Cat. No.: HY-111363

Copy Link Print Information

MK8722

27 Cited Publications

Customer Review

Based on 27 publication(s) in Google Scholar

MK8722 is a potent and systemic pan-AMPK activator.

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 1394371-71-1
Formula: C₂₄H₂₀ClN₃O₄
Molecular Weight:449.89

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

MK8722 Chemical Structure

CAS No.: 1394371-71-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (27)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

MK8722 is a potent and systemic pan-AMPK activator.

IC₅₀ & Target^[1]

AMPK

All AMPK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Sf9	EC₅₀	0.0014 μM Compound: 32; MK-8722	Activation of rat hepatocytes AMPK alpha1/beta1/gamma1 expressed in baculovirus infected Sf9 cells Activation of rat hepatocytes AMPK alpha1/beta1/gamma1 expressed in baculovirus infected Sf9 cells	[PMID: 31930920]
Sf9	EC₅₀	0.0075 μM Compound: 32; MK-8722	Activation of rat hepatocytes AMPK alpha1/beta2/gamma1 expressed in baculovirus infected Sf9 cells Activation of rat hepatocytes AMPK alpha1/beta2/gamma1 expressed in baculovirus infected Sf9 cells	[PMID: 31930920]
Sf9	EC₅₀	1 nM Compound: MK-8722	Activation of recombinant human AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Activation of recombinant human AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31358465]
Sf9	EC₅₀	1 nM Compound: MK-8722	Activation of recombinant mouse AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Activation of recombinant mouse AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31358465]
Sf9	EC₅₀	1 nM Compound: MK-8722	Activation of recombinant rhesus monkey AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay Activation of recombinant rhesus monkey AMPK expressed in Sf9 cells using SAMS peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	[PMID: 31358465]

In Vitro

MK8722 (MK-8722) is a potent, direct, allosteric activator of all 12 mammalian AMPK complexes. MK8722 activates pAMPK complexes with increased potency and magnitude versus AMP, with EC₅₀ values of ~1 to 60 nM and increased activation by factors of ~4 to 24. Although MK8722 exhibits higher affinity for β1-containing (~1 to 6 nM) versus β2-containing (~15 to 63 nM) pAMPK complexes, it is the most potent activator of β2 complexes reported to date. pAMPK activation by maximal AMP plus MK8722 is synergistic, demonstrating that the agents act at distinct sites^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Chronic antihyperglycemic efficacy of MK8722 (MK-8722) is evaluated in db/db mice, a leptin receptor-deficient T2DM model. Once-daily administration of MK8722 results in dose-dependent lowering of ambient blood glucose. On treatment day 12, glucose reductions after MK8722 treatment (30 mpk/day) are comparable to those observed with the PPARγ agonist BRL49653 (3 mpk/day). Unlike BRL49653, the glucose-lowering action of MK8722 manifests without significant effects on body weight, which is a consistent finding. Dose-dependent increases in tissue pACC are maintained throughout the dosing period. Chronic efficacy, without tachyphylaxis, is also observed in additional dysmetabolic and diabetic rodent models. In all cases, efficacy is associated with trough MK8722 plasma levels comparable to the concentrations required to acutely stimulate skeletal muscle glucose uptake. Chronic MK8722 dosing in mice also increases muscle Glut4 protein levels, possibly contributing to efficacy^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1394371-71-1
Appearance Solid
Molecular Weight 449.89
Formula C₂₄H₂₀ClN₃O₄
Color White to off-white
SMILES

O[C@H]1[C@@]([C@]2([H])OC1)([H])OC[C@H]2OC3=NC4=NC(C(C=C5)=CC=C5C6=CC=CC=C6)=C(Cl)C=C4N3
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (27)

All WBCell Proliferation/Viability AssayHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nat Metab

The unique catalytic properties of PSAT1 mediate metabolic adaptation to glutamine blockade. [Abstract]

2024 Aug;6(8):1529-1548. PMID: 39192144

MK8722 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2024 Aug;6(8):1529-1548. [Abstract]

Western blot analysis of PHGDH and AMPK pathway proteins in lysates of MDA-MB-231 cells treated for 48 h with the AMPK activator MK8722 (0-100 μM).

MK8722 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2024 Aug;6(8):1529-1548. [Abstract]

Sensitivity of MDA-MB-231, BT-549, and Hs 578T cells to CB-839 treatment after 24 h pre-treatment with 50 μM MK8722 to activate the adaptive AMPK signaling axis.

MK8722 purchased from MedChemExpress. Usage Cited in: Nat Metab. 2024 Aug;6(8):1529-1548. [Abstract]

Western blot analysis of PHGDH and AMPK pathway proteins in lysates of MDA-MB-231 cells treated with 50 μM MK8722 for the indicated durations (0-48 h).
Nat Cell Biol

TOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy. [Abstract]

2026 Apr;28(4):812-827. PMID: 41803502
Nat Cell Biol

De novo pyrimidine biosynthetic complexes support cancer cell proliferation and ferroptosis defence. [Abstract]

2023 Jun;25(6):836-847. PMID: 37291265
Mol Cell

Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53. [Abstract]

2021 Feb 4;81(3):629-637.e5. PMID: 33400924
Nat Commun

Redefining the role of AMPK in autophagy and the energy stress response. [Abstract]

2023 May 24;14(1):2994. PMID: 37225695

MK8722 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 24;14(1):2994. [Abstract]

Western blot analysis of PHGDH and AMPK pathway proteins in lysates of MDA-MB-231 cells treated with 50 μM MK8722 for the indicated durations (0-48 h).

MK8722 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 24;14(1):2994. [Abstract]

MK8722 (60 mg/kg; ip) inhibited Torin1-induced autophagy in the liver and gastrocnemius muscle of mice.
Autophagy

AMPK promotes TFEB transcriptional activity through dephosphorylation at both MTORC1-dependent and -independent sites. [Abstract]

2026 Feb 9. PMID: 41661247
Autophagy

TNF-induced necroptosis initiates early autophagy events via RIPK3-dependent AMPK activation, but inhibits late autophagy. [Abstract]

2021 Dec;17(12):3992-4009. PMID: 33779513
J Adv Res

MK8722 alleviates osteoarthritis by activating Sesn2 and transcriptionally upregulating BNIP3 to promote mitophagy and inhibit chondrocyte ferroptosis. [Abstract]

2025 Oct 10:S2090-1232(25)00764-7. PMID: 41077348
Sci Adv

2026 Apr 10;12(15).
Biochem Pharmacol

AMPK phosphorylation of KCa2.3 alleviates angiotensin II-induced endothelial dysfunction. [Abstract]

2025 Mar 18:116880. PMID: 40112931
Biochem Pharmacol

AMPK upregulates KCa2.3 channels and ameliorates endothelial dysfunction in diet-induced obese mice. [Abstract]

2021 Jan;183:114337. PMID: 33186592
Front Pharmacol

Berberine stimulates lysosomal AMPK independent of PEN2 and maintains cellular AMPK activity through inhibiting the dephosphorylation regulator UHRF1. [Abstract]

2023 Apr 18:14:1148611. PMID: 37144221
FASEB J

The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscle. [Abstract]

2024 Dec 15;38(23):e70199. PMID: 39611312
J Lipid Res

Aerobic glycolysis drives differentiation of unilocular adipocytes. [Abstract]

2026 Mar 16:101023. PMID: 41850682
iScience

Targeted dephosphorylation of TFEB promotes its nuclear translocation. [Abstract]

2024 Jun 29;27(8):110432. PMID: 39081292
Sci Rep

The gastrointestinal tract is a major source of the acute metformin-stimulated rise in GDF15. [Abstract]

2024 Jan 22;14(1):1899. PMID: 38253650
Sci Rep

AMPK activates Parkin independent autophagy and improves post sepsis immune defense against secondary bacterial lung infections. [Abstract]

2021 Jun 11;11(1):12387. PMID: 34117280
STAR Protoc

Evaluation of AMPK activity in mice by measuring activator-induced glucose uptake. [Abstract]

2021 Jul 17;2(3):100496. PMID: 34337440
bioRxiv

2026 May 21.
bioRxiv

A Far-Red FRET biosensor for AMPK enables multiplexed imaging of single-cell bioenergetic homeostasis. [Abstract]

2026 May 18:2026.05.13.723899. PMID: 42182114
bioRxiv

2025 Sep 29.
bioRxiv

2025 Aug 20.
bioRxiv

Multi-site phosphorylation of BCL2L13 in a TBK1- and AMPK-dependent manner reveals new modes of mitophagy regulation. [Abstract]

2025 Jul 11:2025.07.10.663832. PMID: 40672348
bioRxiv

AMPK activation prevents hepatocellular carcinoma development through inhibition of HNF4α activity. [Abstract]

2025 May 19:2025.05.16.652569. PMID: 40475397
bioRxiv

2024 October 25.
bioRxiv

2024 September 09.
bioRxiv

2024 Mar 1.

Solvent & Solubility

In Vitro:

DMSO : 31.25 mg/mL (69.46 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2228 mL

11.1138 mL

22.2277 mL

5 mM

0.4446 mL

2.2228 mL

4.4455 mL

10 mM

0.2223 mL

1.1114 mL

2.2228 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.62 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.08 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[1]

Mice^[1]
Housing Lean C57BL/6 mice at 10-12 weeks of age and C57BL/6 eDIO mice at 16 weeks of age are used. db/db mice at 7 weeks of age are used. Animals are maintained on a 12 hr/12 hr light-dark cycle with free access to food and water with the temperature maintained at 22ºC. Four lean C57BL/6 mice are housed in a standard cage. eDIO mice are individually caged. Eight db/db mice are housed in a large rodent cage. C57BL/6 mice and db/db mice are maintained on regular rodent chow diet 7012 (5% dietary fat; 3.75 kcal/g) for 1-2 weeks before receiving compound treatments. eDIO mice are maintained on 60% kcal% fat diet. Oral dosing of MK8722 in standard vehicle, or vehicle alone, is performed using 10 mL/kg body weight. The effect of MK8722 on various metabolic parameters is established by comparison to vehicle treated animals^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Myers RW, et al. Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiachypertrophy. Science. 2017 Aug 4;357(6350):507-511. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2228 mL	11.1138 mL	22.2277 mL	55.5691 mL
	5 mM	0.4446 mL	2.2228 mL	4.4455 mL	11.1138 mL
	10 mM	0.2223 mL	1.1114 mL	2.2228 mL	5.5569 mL
	15 mM	0.1482 mL	0.7409 mL	1.4818 mL	3.7046 mL
	20 mM	0.1111 mL	0.5557 mL	1.1114 mL	2.7785 mL
	25 mM	0.0889 mL	0.4446 mL	0.8891 mL	2.2228 mL
	30 mM	0.0741 mL	0.3705 mL	0.7409 mL	1.8523 mL
	40 mM	0.0556 mL	0.2778 mL	0.5557 mL	1.3892 mL
	50 mM	0.0445 mL	0.2223 mL	0.4446 mL	1.1114 mL
	60 mM	0.0370 mL	0.1852 mL	0.3705 mL	0.9262 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MK8722

Epigenetics Compound Library

PI3K/Akt/mTOR Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Pain-Related Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MK8722

All AMPK Isoforms

Biological Activity

Chemical Information

Publications (27)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK8722

Epigenetics Compound Library

PI3K/Akt/mTOR Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Pain-Related Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) MK8722

All AMPK Isoforms

Biological Activity

Chemical Information

Publications (27)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK8722 Related Classifications

Cat. No.: HY-111363